Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A140 vs Erbitux Combined With mFOLFOX6 in First-line Ras Wild-type mCRC
NCT04835142Phase 3Completed
- Sponsor
- Kelun-Biotech
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by Kelun-Biotech. Started Dec 2020; status: completed.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04835142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835142.